Iktos
Charles-Henry Dion has a diverse work experience in the biotech and healthcare industry. Charles-Henry is currently working as a Business Development Manager at Iktos since September 2020. Prior to that, they worked as a Strategic Partnership Manager - Antimicrobials at BIOASTER from January 2019 to September 2019.
Before joining BIOASTER, Charles-Henry worked at Business France (Export) in various roles. Charles-Henry started as a Trade Advisor in Biotechnology & Pharmaceuticals from February 2012 to February 2014. Charles-Henry then served as a Senior Trade Advisor in the Health Department from February 2014 to September 2014. From September 2014 to April 2018, they worked as a Senior Manager North America in the Life Sciences & Healthcare Department, managing the healthcare team for the North American export branch of Business France.
In addition, Charles-Henry worked as a Global Project Manager in the Biotech & Healthcare department at Business France from April 2018 to January 2019, overseeing biotech, pharmaceutical, medtech, and ehealth activities.
Prior to their work at Business France, Charles-Henry worked as a Consultant in Life Sciences at Capgemini Engineering from May 2011 to January 2012. Charles-Henry also gained research experience at Sanofi Pasteur, where they worked as a Research Associate in the Molecular Microbiology Department from February 2010 to August 2010, and at CNRS and INSERM as a Research Associate.
Charles-Henry Dion completed their Bachelor of Sciences in Life Sciences from Université de Tours from 2005 to 2007. Charles-Henry then pursued an Engineer's degree in Biotechnology from Polytech Marseille between 2007 and 2010. Additionally, they obtained a Master of Science (MSc) in Management, Business & Economics from KEDGE Business School, where they studied from 2008 to 2011.
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.